Shares of Alaska Air Group (NYSE: ALK) were up 1.3% in afternoon trade on Thursday. The stock dropped 5% over the past three months but has gained 4% in the past one week. It is currently trading 7% below its 52-week high of $72.22.
The company operates in a highly competitive industry and faces several risks such as economic conditions, volatility in fuel prices and unexpected aircraft incidents. Alaska’s revenue initiatives, particularly its Saver Fare product, as well as its network expansion efforts helped drive revenue and capacity growth in 2019.
The airline also saw a 2% increase in unit costs, ex fuel and special items, during 2019. This increase is expected to continue in 2020 due to wage inflation, higher engine maintenance on some of its fleets, and higher lease return costs associated with its Airbus fleet.
Alaska is focused on reducing its overhead, improving its productivity and managing its vendor costs. The company is also taking steps to manage its fuel costs by flying bigger, more fuel-efficient aircraft thereby improving its fuel efficiency.
In 2019, Alaska saw a 6% growth in total revenues with a 4.2% increase in unit revenues. Capacity increased 2%, fueled by network expansion and fleet growth. The aforementioned revenue initiatives are expected to drive incremental revenue in 2020 as well.
Alaska expects to increase its network capacity by approx. 3-4% in 2020, but this guidance is heavily dependent on the return to service of the Boeing 737 Max aircraft. The company currently expects 10 737 Max aircraft to be delivered in 2020 but if the grounding delays these deliveries, the capacity growth might be negatively impacted.
Analysts are forecasting earnings of $7.04 per share on revenue of $9.18 billion for 2020. The majority of analysts have rated the stock as Buy and it has an average price target of $76.60, representing an upside of 15% from the current level.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
